» Articles » PMID: 27344645

A Modified Enzymatic Method for Measurement of Glycogen Content in Glycogen Storage Disease Type IV

Overview
Journal JIMD Rep
Publisher Wiley
Date 2016 Jun 27
PMID 27344645
Citations 3
Authors
Affiliations
Soon will be listed here.
Abstract

Deficiency of glycogen branching enzyme in glycogen storage disease type IV (GSD IV) results in accumulation of less-branched and poorly soluble polysaccharides (polyglucosan bodies) in multiple tissues. Standard enzymatic method, when used to quantify glycogen content in GSD IV tissues, causes significant loss of the polysaccharides during preparation of tissue lysates. We report a modified method including an extra boiling step to dissolve the insoluble glycogen, ultimately preserving the glycogen content in tissue homogenates from GSD IV mice. Muscle tissues from wild-type, GSD II and GSD IV mice and GSD III dogs were homogenized in cold water, and homogenate of each tissue was divided into two parts. One part was immediately clarified by centrifugation at 4°C (STD-prep); the other part was boiled for 5 min then centrifuged (Boil-prep) at room temperature. When glycogen was quantified enzymatically in tissue lysates, no significant differences were found between the STD-prep and the Boil-prep for wild-type, GSD II and GSD III muscles. In contrast, glycogen content for GSD IV muscle in the STD-prep was only 11% of that in the Boil-prep, similar to wild-type values. Similar results were observed in other tissues of GSD IV mice and fibroblast cells from a GSD IV patient. This study provides important information for improving disease diagnosis, monitoring disease progression, and evaluating treatment outcomes in both clinical and preclinical clinical settings for GSD IV. This report should be used as an updated protocol in clinical diagnostic laboratories.

Citing Articles

Natural history study of hepatic glycogen storage disease type IV and comparison to Gbe1ys/ys model.

Koch R, Kiely B, Choi S, Jeck W, Flores L, Sood V JCI Insight. 2024; 9(12).

PMID: 38912588 PMC: 11383185. DOI: 10.1172/jci.insight.177722.


An optimized method for tissue glycogen quantification.

Schaubroeck K, Leitner B, Perry R Physiol Rep. 2022; 10(4):e15195.

PMID: 35179318 PMC: 8855679. DOI: 10.14814/phy2.15195.


Alglucosidase alfa treatment alleviates liver disease in a mouse model of glycogen storage disease type IV.

Yi H, Gao F, Austin S, Kishnani P, Sun B Mol Genet Metab Rep. 2016; 9:31-33.

PMID: 27747161 PMC: 5053031. DOI: 10.1016/j.ymgmr.2016.09.008.

References
1.
Yi H, Brooks E, Thurberg B, Fyfe J, Kishnani P, Sun B . Correction of glycogen storage disease type III with rapamycin in a canine model. J Mol Med (Berl). 2014; 92(6):641-50. DOI: 10.1007/s00109-014-1127-4. View

2.
Mercier C, WHELAN W . The fine structure of glycogen from type IV glycogen-storage disease. Eur J Biochem. 1970; 16(3):579-83. DOI: 10.1111/j.1432-1033.1970.tb01120.x. View

3.
Mochel F, Schiffmann R, Steenweg M, Akman H, Wallace M, Sedel F . Adult polyglucosan body disease: Natural History and Key Magnetic Resonance Imaging Findings. Ann Neurol. 2012; 72(3):433-41. PMC: 4329926. DOI: 10.1002/ana.23598. View

4.
Huijing F . Glycogen metabolism and glycogen-storage diseases. Physiol Rev. 1975; 55(4):609-58. DOI: 10.1152/physrev.1975.55.4.609. View

5.
Sun B, Bird A, Young S, Kishnani P, Chen Y, Koeberl D . Enhanced response to enzyme replacement therapy in Pompe disease after the induction of immune tolerance. Am J Hum Genet. 2007; 81(5):1042-9. PMC: 2265658. DOI: 10.1086/522236. View